True, one of the drugmaker's leading candidates, CagriSema, recently failed to impress investors in a phase 3 study. Upon closer inspection, though, Novo Nordisk's "disappointing" late-stage ...

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

J.P. Morgan has once again picked Boston Scientific (NYSE:BSX) and Intuitive Surgical (NASDAQ:ISRG) as its top large-cap picks in MedTech for the new year, and reaffirmed insulin pump maker ...

Ahead of the 2025 J.P. Morgan Healthcare Conference scheduled to take place in a few days, Oppenheimer named five potential buyout candidates in biotech on Friday, naming obesity drug developer ...

Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of its next-generation obesity drug candidate CagriSema did not reach the ...

Long-sleeved T-shirts are an underrated wardrobe staple. As stylist and fashion designer Jordan Page of @veryadvanced points out, the humble long-sleeved tee can look “classier than short ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Healthcare & Pharmaceuticalscategory Lilly obesity drug Mounjaro to be offered in Britain's NHS after watchdog nod December 24, 2024 Healthcare & Pharmaceuticalscategory US FDA approves Hikma's ...

This was due to disappointing late-stage trial results for its experimental weight-loss drug, CagriSema. Novo Nordisk has partnered with Photys Therapeutics to develop a novel therapeutic ...